Treatment Approach for Acute Hepatitis B with Elevated BAP Score

Indications for Treatment in Acute Hepatitis B

The American Association for the Study of Liver Diseases recommends antiviral therapy with entecavir or tenofovir for patients with acute hepatitis B and elevated BAP score, indicated by total bilirubin >3 mg/dL, international normalized ratio >1.5, encephalopathy, or ascites 1, 2
Treatment is indicated for patients with fulminant hepatitis B, as recommended by the European Association for the Study of the Liver 1, 3
The American Association for the Study of Liver Diseases recommends treatment for patients with severe or protracted acute hepatitis B 2, 4

Entecavir or tenofovir are preferred first-line treatment options due to their high potency and high genetic barrier to resistance, as recommended by the American Gastroenterological Association 2, 5
Lamivudine has been used historically but has a lower barrier to resistance, according to the Asian Pacific Association for the Study of the Liver 3, 4

The American Association for the Study of Liver Diseases recommends monitoring HBV DNA levels to assess virological response 1, 3
Regular assessment of liver function tests (ALT, bilirubin, INR) is recommended by the European Association for the Study of the Liver 2, 3

The American Association for the Study of Liver Diseases recommends continuing antiviral therapy for at least 3 months after seroconversion to anti-HBs 4
The European Association for the Study of the Liver recommends continuing treatment for at least 6 months after HBeAg seroconversion if only HBeAg seroconversion occurs without HBsAg loss 4

Tenofovir is preferred during pregnancy as it is classified as FDA pregnancy category B, according to the American College of Obstetricians and Gynecologists 4
The American Association for the Study of Liver Diseases recommends longer treatment durations for immunosuppressed patients with acute hepatitis B 4

The American Association for the Study of Liver Diseases recommends monitoring for HBsAg clearance and anti-HBs seroconversion 3, 4
Regular assessment of liver function tests until complete normalization is recommended by the European Association for the Study of the Liver 1, 3

The American Association for the Study of Liver Diseases recommends distinguishing between true acute hepatitis B and reactivation of chronic hepatitis B for treatment decisions 4
Non-adherence to medication is a common cause of virological breakthrough rather than true resistance, according to the American Gastroenterological Association 5
The BAP score should be interpreted in context with other clinical and laboratory parameters, not in isolation, as recommended by the European Association for the Study of the Liver 1, 2

The American Association for the Study of Liver Diseases recommends that acute hepatitis B recovers spontaneously in more than 95% of cases, so antiviral therapy is generally not recommended 6, 7
Early initiation of antiviral therapy may interfere with normal protective immune response and potentially increase the risk of progression to chronic hepatitis, as suggested by the European Association for the Study of the Liver 7
Oral antiviral therapy should be considered only in cases of persistent severe hepatitis or acute liver failure, according to the American Association for the Study of Liver Diseases 7, 8

When treatment is indicated for acute hepatitis B, lamivudine, telbivudine, or entecavir is preferred due to their rapid onset of action, as recommended by the American Association for the Study of Liver Diseases 8
In a randomized controlled trial of severe acute hepatitis B, lamivudine treatment showed significantly lower HBV DNA levels after 4 weeks compared to control, but similar rates of HBsAg clearance after 12 months, as reported by the European Association for the Study of the Liver 7

For HBeAg-positive chronic hepatitis B with flare, treatment should be initiated with nucleos(t)ide analogues (NAs) such as entecavir or tenofovir if ALT is greater than 2 times normal or moderate/severe hepatitis on biopsy, as recommended by the American Association for the Study of Liver Diseases 9, 10, 11
For HBeAg-negative chronic hepatitis B with flare, treatment is recommended if serum HBV DNA ≥10^5 copies/mL and ALT ≥2 times normal, according to the European Association for the Study of the Liver 9, 11
Patients with compensated cirrhosis are best treated with nucleos(t)ide analogues rather than interferon due to the risk of hepatic decompensation associated with interferon-related flares, as suggested by the American Association for the Study of Liver Diseases 9, 12

For chronic HBV with flare, long-term treatment is often required, with a minimum of 1 year for HBeAg-positive patients, continuing 3-6 months after HBeAg seroconversion, as recommended by the European Association for the Study of the Liver 11
Nucleos(t)ide analogues with high genetic barriers to resistance (entecavir, tenofovir) are preferred for both acute and chronic hepatitis B when treatment is needed, according to the American Association for the Study of Liver Diseases 13, 14